Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Chemist to Study ‘Orally Effective Therapy’ to Fight Obesity

Published: Thursday, August 15, 2013
Last Updated: Thursday, August 15, 2013
Bookmark and Share
A chemist has received a federal grant to study the oral administration of PYY3-36, a peptide that inhibits food intake by naturally switching off one's appetite.

The project is said to have major implications for people struggling with obesity and associated diseases, such as cardiovascular disease and diabetes.

Robert Doyle, associate professor of chemistry, has been awarded $221,000 by the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health. His project will last for two years, with the option of a third, and will involve Christian L. Roth, a pediatric endocrinologist at Seattle Children’s Hospital.

The award comes on the heels of a landmark decision by the American Medical Association to categorize obesity as a disease requiring a “range of interventions,” including weight-loss counseling, medication and surgery.

“Obesity is one of today’s leading health challenges—not only in North America and Europe, but also in Asia and Australia,” says Doyle, whose expertise spans chemistry and biology. “The prevalence of obesity among children and adolescents is of particular concern, despite public health education and initiatives.”

At the heart of Doyle's project is PYY3-36, a gut hormone that presumably supports the long-term benefits of bariatric surgery—currently, the only effective long-term exogenous treatment for obesity.
Doyle plans to utilize vitamin B12, which supports functioning of the brain and nervous system, to help protect and carry PYY3-36 through the gastrointestinal tract.

“We will trick the digestive system into carrying our peptide [PYY3-36], along with the B12,” says Doyle, who also holds faculty appointments in biology and biochemistry. “PYY3-36 will then send messages between the intestine and the brain, as well as in the brain, itself, telling you when you’re full. That’s why it’s called the ‘satiety peptide.’”

Since pharmacotherapy is merely an adjunct treatment for obesity management, the race is on to develop novel anti-obesity drugs that are safe and effective.

Doyle believes that orally effective therapy—particularly involving PYY3-36’s appetite-suppressing properties—may be the way forward.

“Ultimately, we want to develop an oral formulation that takes advantage of our bodies’ own appetite-control elements,” he says. “But first, we need to study its effects.”

Doyle, who earned a Ph.D. from Trinity College in Dublin, joined SU’s faculty in 2005. Since then, he has produced award-winning research that may lead to new treatments and diagnostic tools for diabetes and cancer. Much of his work, such as the utilization of B12 to orally deliver proteins, draws on chemical or systems biology research.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Chemists Design ‘Smart’ Nanoparticles to Improve Drug Delivery, DNA Self-Assembly
A team of chemists has used a temperature-sensitive polymer to regulate DNA interactions in both a DNA-mediated assembly system and a DNA-encoded drug-delivery system.
Thursday, August 15, 2013
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!